Lake Street initiated coverage of Daxor with a Buy rating and $23 price target, calling it an "overlooked high-growth MedTech diagnostic company addressing a multi-billion-dollar" total addressable market focused on accurate blood volume analysis. The firm thinks the Street is missing the underlying fundamental strength of Daxor's operating business given Daxor's filing status as a 1940 Act Investment Fund, the analyst added.
